Sign inJoin waitlistJoin the waitlist

Brendan Curti

Robert W. Franz Endowed Chair for Clinical Research · Providence Health & Services - Oregon

Credentials: · · · ·

History

Swedish Medical Center
Present
Providence Health & Services - Oregon
Present

MedStar Georgetown University Hospital
1988–1990
Internal Medicine
Penn State Milton S Hershey Medical Center
1985–1988
Georgetown University School of Medicine
1981–1985

Research

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Journal of Clinical Oncology · 2015 · 2,112 citations
Sunitinib in patients with metastatic renal cell carcinoma
JAMA · 2006 · 981 citations
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
New England Journal of Medicine · 2021 · 741 citations

WU
Walter Urba
39 papers
DL
Dan Longo
22 papers
JJ
John Janik
17 papers
David McDermott
16 papers
BG
Barry Gause
15 papers
Joseph Clark
14 papers
HK
Howard Kaufman
13 papers
Gregory Daniels
11 papers
John Kirkwood
11 papers
Marc Ernstoff
11 papers
Mario Sznol
11 papers
MC
Marka Crittenden
10 papers · 1 as a resident

Grants

Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response
National Cancer Institute · R01
Contact PI · $3M · Providence Portland Medical Center
2021–2027
Ipilimumab Plus a Galectin-3 Inhibitor for Metastatic Melanoma
National Cancer Institute · R21
Contact PI · $339K · Providence Portland Medical Center
2015–2018
Clinical and Immunological Effects of SBRT and IL-2 in Metastatic Melanoma
National Cancer Institute · R21
PI · $349.3K · Providence Portland Medical Center
2013–2016
Clinical Development of Anti-OX40 and OX40L
National Cancer Institute · R01
Contact PI · $1.4M · Providence Portland Medical Center
2004–2010

Clinical trials

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
Principal investigator · Active not recruiting · Phase 2
Providence Health & Services
2024–2027
GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
Principal investigator · Withdrawn · Phase 2
Providence Health & Services
2023–2031
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
Principal investigator · Completed · Phase 1
Providence Health & Services
2016–2022
Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)
Principal investigator · Completed · Phase 1
Viralytics
2015–2019